Agenda 2024
|
|
|
|---|---|
| 8:00 am | REGISTRATION AND BREAKFAST |
| 8:25 am | Erle Robertson Ph.D., Vice Chair of Otorhinolaryngology–Head and Neck Surgery, Professor of Microbiology Perelman School of Medicine, University of Pennsylvania ♦ Opening Remarks |
| First Session | Moderator: Dr. Harvey Freedman, MD, Professor of Medicine, University of Pennsylvania, Philadelphia, PA |
| 8:30 – 9:00 am | Dr. Sumita Bhaduri-McIntosh, M.D., Ph.D., Professor, Dept. of Pediatrics, University of Florida, FL ♦ “A selective HDAC3 and HDAC8 PROTAC as a novel oncolytic approach for EBV-cancers”. |
| 9:00 – 9:20 am | Dr. Tauseef Butt, PhD, President, Progenra Inc, Malvern, PA ♦ “Enhancing HSV-2 target protein expression by SUMO-fusion at the mRNA level”. |
| 9:20 – 9:40 am | Dr. Sita Awasthi, Associate Professor Research, University of Pennsylvania, PA ♦ “mRNA encoding HSV mono and bispecific antibodies for mitigation of herpes virus associated diseases.” |
| 9:40 – 10:00 am | Dr. Anna Grosskopf, PhD, Postdoctoral Visiting Fellow, Dr. Laurie Krug Lab, HIV & AIDS Malignancy Branch NCI, Bethesda, MD ♦ ”Eph receptor tyrosine kinases are functional entry receptors for the murine gammaherpesvirus 68”. |
| 10:00 – 10:30 am | COFFEE BREAK |
| Second session | Moderator: Dr. Laurie Krug, Stadtman Investigator, National Cancer Institute, Bethesda, MD |
| 10:30 – 11:30 am | Dr. Robert Yarchoan, MD, Chief, HIV and AIDS Malignancy Branch, CCR, NCI, Bethesda MD and Director, Office of HIV and AIDS Malignancy, NCI ♦ Gertrude and Werner Henle Lectureship Keynote Speaker ♦ “KSHV-Associated Diseases: Insights on Pathogenesis and Novel Approaches to Treatment”. |
| 11:30 – 11:50 am | Dr. Paula Krosky, Director, Merck, West Point, PA ♦ “Broad spectrum inhibitors of herpesvirus replication”. |
| 11:50am – 12:10 pm | Dr. Dipayan Bose, PhD, Research Associate, Dr. Erle Robertson Lab, University of Pennsylvania, Philadelphia, PA ♦ "Differential IFN signaling due to altered M6A modification in host epitranscriptome during lytic EBV infection". |
| 12:10 – 1:30 pm | LUNCH |
| Third session | Moderator: Dr. Jianxin You, Professor, University of Pennsylvania, Philadelphia, PA |
| 1:30 – 2:00 pm | Dr. Joseph Ziegelbauer, PhD, Deputy Chief, HIV and AIDS Malignancy Branch, Bethesda, MD ♦ “Spatial Transcriptomics of Patients with Kaposi Sarcoma Identifies Mechanisms of Immune Evasion”. |
| 2:00 – 2:20 pm | Dr. Michael McIntosh, PhD, Associate Professor, Department of Pediatrics, University of Florida, FL ♦ “Genomic Analysis of Synthetic Lethal Sensitive and Resistant Cell Lines Derived from EBV+ and EBV– Diffuse Large B-cell Lymphomas”. |
| 2:20 – 2:40 pm | Ms. Samantha Sustek, PhD Candidate, Paul Lieberman Lab, Wistar Institute, Philadelphia, PA ♦ “Cryo-EM studies of EBNA1 in complex with human telomeric factors TRF2-hRAP1 at the EBV oriP”. |
| 2:40 – 3:00 pm | Dr. Malay Kumar Sannigrahi, Research Associate, Dr. Dev Basu Lab, University of Pennsylvania, Philadelphia, PA ♦ “Variation in HPV E6-mediated repression of the PGC-1α/ERRα axis determines oropharyngeal cancer treatment responses and defines new therapeutic targets”. |
| 3:00 – 3:30 pm | AFTERNOON BREAK |
| Final Session | Moderator: Dr. Yanming Du, PhD, Professor, Baruch S. Blumberg Institute, Doylestown, PA |
| 3:30 – 4:00 pm | Dr. Ahmed Diab, PhD, University of Pennsylvania, Philadelphia, PA ♦ “WEE1 inhibition triggers tumor microenvironment-dependent antitumor immunity against HPV+ HNSCC tumors”. |
| 4:00 – 4:20 pm | Ms. Ameera Mungale, PhD Candidate, Joseph M. Ziegelbauer Lab National Cancer Institute, Bethesda, MD ♦ “Vascular endothelial growth factor receptor 3 (VEGFR3/FLT4) regulates the KSHV replication cycle”. |
| 4:2 – 4:40 pm | Taylor Senay, PhD Candidate, Jianxin You Lab, University of Pennsylvania, Philadelphia, PA ♦ “Merkel cell polyomavirus protein ALTO modulates TBK1 activity to support persistent infection”. |
| 4:40 – 5:00 pm | Dr. Anuj Ahuja, Postdoctoral Fellow, Dr. Ethel Cesarman Lab, Weill Cornell Medical College, New York, NY ♦ “Targeting HERV-K by ART drugs for the treatment of Primary Effusion Lymphoma”. |
| 5:00 pm | RECEPTION |
